Browse > Article
http://dx.doi.org/10.15324/kjcls.2022.54.2.95

Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years  

Seo, Yo-Han (Department of Laboratory Medicine, Gwangju Veterans Hospital)
Shin, Hee-Young (Department of Biomedical Science, Chonnam National University Medical School)
Publication Information
Korean Journal of Clinical Laboratory Science / v.54, no.2, 2022 , pp. 95-102 More about this Journal
Abstract
The relationship between lipoprotein(a) and dyslipidemia is not clear. This study was therefore undertaken to investigate the relationship between lipoprotein(a) and dyslipidemia in elderly patients over 60 years. From 2014 to 2020, a total of 2,580 adults aged 60 years or older (73.31±7.24 years, 1,954 males) were enrolled in the study. The patients had checked into a general hospital, and data were obtained for lipoprotein(a), LDL-C, TG, HDL-C, hs-CRP, HbA1c, sex, age, BMI, dyslipidemia diagnosis, and use of lipid-lowering agents. BMI and HbA1c showed no correlation with lipoprotein(a), but hs-CRP (r=0.138), LDL-C (r=0.097), HDL-C (r=-0.089), TG (r=-0.073), and age (r=0.072) were significantly correlated to lipoprotein(a). The partial correlation between lipoprotein(a) and LDL-C, which was adjusted for variables, was significant only in the male gender (r=0.158, P<0.001). As the odds ratio of the 4th quartile of lipoprotein(a) (OR=1.376, 95% CI=1.038~1.822) for dyslipidemia was found to be significant in this study when the level of LDL-C, the primary target, could not be reduced even by taking lipid-lowering drugs, we propose that lipoprotein(a) should also be included among the several factors considered as secondary targets. Our results indicate that studies on various lipid factors considering the sex, age, types and use of lipid-lowering agents, are warranted.
Keywords
Dyslipidemia; LDL cholesterol; Lipoprotein(a);
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, et al. Lipoprotein (a)-cholesterol and coronary heart disease in the framingham heart study. Clin Chem. 1999;45:1039-1046. https://doi.org/10.1093/clinchem/45.7.1039   DOI
2 Sahebkar A, Serban M, Penson P, Gurban C, Ursoniu S, Toth P, et al. Lipid and blood pressure meta-analysis collaboration (LBPMC) group. the effects of tamoxifen on plasma lipoprotein (a) concentrations: systematic review and meta-analysis. Drugs. 2017;77:1187-1197. https://doi.org/10.1007/s40265-017-0767-4   DOI
3 Wang J, Hu B, Kong L, Cai H, Zhang C. Native, oxidized lipoprotein (a) and lipoprotein (a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta. 2008;390:67-71. https://doi.org/10.1016/j.cca.2007.12.015   DOI
4 Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med. 1986;314:488-500. https://doi.org/10.1056/NEJM198602203140806   DOI
5 Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjold B, Hynes N, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. Br Med J. 2016;6:e010401. https://doi.org/10.1136/bmjopen-2015-010401   DOI
6 Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G, et al. For the european athersclerosis society consensus panel: lipoprotein(a) as a cardiovascular risk factor; current status. Eur Heart J. 2014;35:1683-1693. https://doi.org/10.1093/eurheartj/ehq386   DOI
7 O'Donoghue ML, Fazio S, Giugliano RP, Stroes ES, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial. Circulation. 2019;139:1483-1492. https://doi.org/10.1161/CIRCULATIONAHA.118.037184   DOI
8 Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K, et al. High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a) multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2021;78:1083-1094. https://doi.org/10.1016/j.jacc.2021.07.016   DOI
9 Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77:1439-1450. https://doi.org/10.1016/j.jacc.2021.01.027   DOI
10 de Isla LP, Masana L, Argueso R, Campuzano R, Egocheaga I, Escobar C, et al. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. Rev Esp Cardiol (Engl Ed). 2020;73:348-353. https://doi.org/10.1016/j.rec.2019.11.019   DOI
11 Ariyo AA, Thach C, Tracy R. Lp (a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108-2115. https://doi.org/10.1056/NEJMoa001066   DOI
12 Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein (a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290:11649-11662. https://doi.org/10.1074/jbc.M114.611988   DOI
13 Knight BL, Perombelon YN, Soutar AK, Wade DP, Seed M. Catabolism of lipoprotein (a) in familial hypercholesterolaemic subjects. Atherosclerosis. 1991;87:227-237. https://doi.org/10.1016/0021-9150(91)90025-X   DOI
14 Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein (a) in men. Am J Cardiol. 1996;77:1244-1247. https://doi.org/10.1016/S0002-9149(96)00174-9   DOI
15 Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011;124:199-205. https://doi.org/10.1016/j.amjmed.2010.09.021   DOI
16 Opoku S, Gan Y, Fu W, Chen D, Addo-Yobo E, Trofimovitch D, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban china: findings from the china national stroke screening and prevention project (CNSSPP). BMC public health. 2019;19:1-15. https://doi.org/10.1186/s12889-019-7827-5   DOI
17 Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab. 2011;96:885-893. https://doi.org/10.1210/jc.2010-2061   DOI
18 Li S, Wu N-Q, Zhu C-G, Zhang Y, Guo Y-L, Gao Y, et al. Significance of lipoprotein (a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis. 2017;260:67-74. https://doi.org/10.1016/j.atherosclerosis.2017.03.021   DOI
19 Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand. 1963;59:369-382. https://doi.org/10.1111/j.1699-0463.1963.tb01808.x   DOI
20 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003   DOI
21 Banach M, Aronow WS, Serban C, Sahabkar A, Rysz J, Voroneanu L, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res. 2015;95:111-125. https://doi.org/10.1016/j.phrs.2015.03.009   DOI
22 Group H-TC. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212. https://doi.org/10.1056/NEJMoa1300955   DOI
23 Sunayama S, Daida H, Mokuno H, Miyano H, Yokoi H, Lee YJ, et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein (a) in women≥ 55 years of age. Circulation. 1996;94:1263-1268. https://doi.org/10.1161/01.CIR.94.6.1263   DOI
24 KSoLA. Korean guidelines for the management of dyslipidemia 4th ed. 2018.
25 Papadopoulos N, Bedynek J. Serum lipoprotein patterns in patients with coronary atherosclerosis. Clin Chim Acta. 1973; 44:153-157. https://doi.org/10.1016/0009-8981(73)90375-6   DOI
26 Rader DJ, Cain W, Zech LA, Usher D, Brewer HB. Variation in lipoprotein (a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein (a) production. J Clin Invest. 1993;91:443-447. https://doi.org/10.1172/JCI116221   DOI